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Effi cacy and Tolerability of Tricyclic 
Antidepressants and SSRIs Compared 
With Placebo for Treatment of Depression 
in Primary Care: A Meta-Analysis
ABSTRACT
PURPOSE Depression is common in primary care. There are no systematic reviews 
of depression treatment comparing antidepressants with placebo; hence, we do 
not know whether these medications are effective in primary care.
METHODS We searched the Cochrane Collaboration Depression, Anxiety and 
Neurosis Group register of controlled trials, MEDLINE, International Pharmaceuti-
cal abstracts, PsycINFO, and EMBASE. Abstracts of potential studies were reviewed 
independently by 2 authors. Studies needed to include randomized controlled tri-
als of either a tricyclic antidepressant (TCA) or selective serotonin reuptake inhibi-
tor (SSRI), or both, and placebo in a primary care setting. The data and quality of 
the studies were extracted and assessed by 2 authors blind to the other’s choice. 
Disagreements were resolved by discussion. The main outcome measures were the 
standardized mean difference and weighted mean difference of the fi nal mean 
depression scores, the relative risk of improvement, and the number withdrawing 
because of side effects. Pooling of results was done using Review Manager 4.2.2.
RESULTS There were 10 studies in which TCAs were compared with placebo, 3 in 
which SSRIs were compared with placebo, and 2 with both compared with pla-
cebo. One half of the studies were of low methodological quality, and nearly all 
studies were of short duration, typically 6 to 8 weeks. Pooled estimates of effi cacy 
data showed a relative risk of 1.26 (95% CI, 1.12-1.42) for improvement with 
TCAs compared with placebo; For SSRIs, relative risk was 1.37 (95% CI, 1.21-
1.55). Most patients, 56% to 60%, responded well to active treatment compared 
with 42% to 47% for placebo. The number needed to treat for TCAs was about 
4, and for SSRIs it was 6. The numbers needed to harm (for withdrawal caused by 
side effects) ranged from 5 to 11 for TCAs and 21 to 94 for SSRIs. Low-dose (100 
mg or 75 mg) as well as high-dose TCAs were effective.
CONCLUSION This systematic review is the fi rst comparing antidepressants with 
placebo for treatment of depression in primary care. Both TCAs and SSRIs are 
effective. This review is also the fi rst to show that low-dose TCAs are effective in 
primary care. Prescribing antidepressants in primary care is a more effective clini-
cal activity than prescribing placebo.
Ann Fam Med 2005;3:449-456. DOI: 10.1370/afm.349.
INTRODUCTION
It is a paradox that whereas the great majority of patients with clini-cal depression are cared for by primary care physicians, most research fi ndings upon which decisions are made have involved secondary care 
patients. This discrepancy is important because research suggests that 
patients with depressive disorders in primary care have different causes, 
abnormalities, and natural history than those of psychiatric inpatients or 
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outpatients.1,2 Often depressed primary care patients 
report somatic symptoms, which include gastrointes-
tinal, skeletal muscle, and cardiovascular complaints, 
as opposed to describing nonsomatic criteria for 
depression. 
Doubts about the effectiveness of antidepressant 
medication and other therapies, such as cognitive ther-
apy, may contribute to the variability in primary care 
management of depression.3,4 Up to 40% of depressed 
patients fail to show a response to fi rst-line antidepres-
sant drug treatment,5 and of those that do respond, 
only a proportion will achieve full recovery.6 One 
cohort study of primary care patients found that 60% 
of depressed patients treated with medication and 50% 
with milder depression still met the criteria for caseness 
at 1 year.7
Recent reports have indicated an urgent need to 
review the evidence of only those studies of antidepres-
sant effi cacy on patient samples based in primary care.8,9 
Several completed reviews and protocols are currently 
registered on the Cochrane database that consider the 
effi cacy of antidepressants for the treatment of depres-
sion. None has specifi ed a focus on patients treated in 
primary care.10 Systematic reviews of antidepressant 
medication often include patients seen in outpatient 
facilities rather than in primary care or at least recruited 
from primary care.11 Concern has been expressed about 
the relevance of secondary care studies to primary care 
patients.8,9 We are aware of only 2 published system-
atic reviews based on patients either seen or recruited 
in primary care. Both compared newer antidepressants 
with older antidepressants. The Mulrow et al review12 
had a small section on antidepressant drugs vs placebo 
but reviewed only 4 studies. The MacGillivray et al 
review13 compared selective serotonin reuptake inhibi-
tors (SSRIs) with tricyclic antidepressants (TCAs) and 
therefore comment only on relative effi cacy. Compari-
son with placebo is needed to obtain absolute effi cacy. 
These considerations indicate a persistent need to 
review the evidence of only those studies that have 
been conducted comparing antidepressant effi cacy with 
placebo using patient samples based in primary care.8,9 
The aim of this review was to review systematically the 
effi cacy of antidepressant compared with placebo stud-
ies in treating depression in primary care. 
METHODS 
Study Selection
Studies were considered for this review if they were 
randomized, placebo-controlled trials using TCAs and/
or SSRIs and included primary care patients. Primary 
care patient samples were defi ned as an undifferenti-
ated group of patients who are able to access medical 
care from a primary health care clinician.14 Participants 
had to be adults who had a diagnosis of depression 
(studies with predominately children or the elderly 
were excluded), because we wished to assess the dos-
age levels in adults, and lower doses of antidepressants 
are often used in the elderly. Studies could be in any 
language.
Our primary outcomes were the effi cacy of TCAs 
and SSRIs in comparison with placebo. Secondary out-
comes were the number reporting drug-related adverse 
events and the number withdrawing because of drug-
related adverse events. We also explored the effect of 
study quality on outcome, the effect of having primary 
care physicians as at least one half of the clinicians 
prescribing medications and assessing patients, and the 
effectiveness of low-dose of medication. 
Data Sources
We electronically searched the Cochrane Collaboration 
Depression, Anxiety and Neurosis Group (CCDAN) 
register, MEDLINE, International Pharmaceutical 
abstracts, PsycINFO, and EMBASE up to February 
2003 for any trials in which antidepressants were used 
in primary care. A follow-up search was done in Sep-
tember 2003, and a fi nal search was done in Decem-
ber 2004. The search terms used were the names of 
all known antidepressant medications. There was no 
language restriction. Two reviewers independently 
assessed abstracts of all studies possible for inclusion for 
relevant study inclusion criteria. We searched for addi-
tional trials in the reference lists of initial studies identi-
fi ed and by scrutinizing other relevant review articles. 
We also contacted selected authors and experts.
Data Extraction
The methodological quality of the selected studies 
was assessed according to the recommendations of the 
Cochrane Collaboration Handbook.15 The components 
of quality were adequacy of sample size, allocation 
concealment, clear description of treatment, repre-
sentative source of subjects, use of diagnostic criteria 
or clear specifi cation of inclusion criteria, and either 
outcome measures described clearly or use of validated 
instruments. A score of 0 on any component caused the 
study to be rated as poor quality. Two reviewers inde-
pendently extracted data using data extraction forms, 
and disagreements were resolved by discussion. A simi-
lar process was used for the validity assessment.
Data Synthesis 
All data were analyzed using Review Manager (Rev-
Man) 4.2.2, which is the Cochrane Collaboration 
software used for preparing systematic reviews. For 
continuous outcomes we calculated the standardized 
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Figure 1. Number of studies from the initial 
search (12 from the initial search and 3 from 
the updated search)
284 studies found
130 for possible inclusion
154 not meeting inclusion
39 studies
91 elderly samples or did 
not study TCA vs SSRI or 
either with placebo
21 for inclusion
18 had no placebo
12 RCTs with suitable 
information (15 in total)
9 excluded eg duplicate data
mean difference. Where the same outcome scale was 
used, we calculated the weighted mean difference. For 
dichotomous outcomes we calculated relative risk (RR) 
and the range of numbers needed to treat for statisti-
cally signifi cant studies. We assessed heterogeneity 
using the Q statistic.15 Where data were available in 
graphic format only, an approximation of the mean was 
made to assess the outcomes. For data reported without 
standard deviations, the highest standard deviations in 
the outcome scores from the other studies were used. 
We also performed a funnel plot analysis to check for 
publication bias. There were a number of defi nitions 
for outcomes we described as “improvement”: 4 defi ni-
tions used ≤50% reduction in the Montgomery-Asberg 
Depression Rating Scale (MADRS),16-19 ≤50% reduction 
in Hamilton Depression Rating Scale (HAMD),20 ≤7 on 
the HAMD scale,21 and ≤4 points on HAMD22; and 3 
defi nitions used global evaluation of improvement.23-25
RESULTS
Of the 284 articles identifi ed from the initial search 
strategy, only 12 met the study criteria (Figure 1). 
Three additional studies were found in a search under-
taken in September 2003. No further studies were 
found in December 2004. There were 890 participants 
in SSRI studies, 596 in TCA studies, and 1,267 patients 
on placebo (Table 1).16-30 Of the 5 possible SSRIs avail-
able, 2 studied sertraline, 3 studied escitalopram (a 
precursor of citalopram), and 1 studied citalopram. 
Of the TCAs available, 2 studied dothiepin, 4 studied 
amitriptyline, 2 studied mianserin, and 3 studied imip-
ramine. Ten of the 15 studies were identifi ed as having 
a competing interest. 
Our results confi rm that both TCA and SSRI are 
signifi cantly effective compared with placebo (Figures 
2 and 3). For depression scores the standardized mean 
difference for TCA vs placebo was -0.42 (95% confi -
dence interval [CI], -0.55 to -0.3). The relative risk for 
improvement using TCA medications was 1.26 (95% 
CI, 1.12 to 1.42). For SSRI medications the relative risk 
for improvement was 1.37 (95% CI, 1.21 to 1.55). The 
number needed to treat for 1 improved patient ranged 
from 3 to 4 for the TCA studies that were statistically 
signifi cant. Likewise, the number needed to treat was 6 
for SSRIs. We performed an analysis with 5 studies (not 
shown) that had treatment group scores of <8 on the 
HAMD. The weighted mean difference was -3.68 (95% 
CI, -5.89 to -1.47).There was no signifi cant heteroge-
neity for any analyses, so a fi xed effects analysis was 
used. No signifi cant differences were found for those 
studies in which means were approximated from graphs 
or standard errors were assumed from other studies 
compared with studies that had published data. A fun-
nel plot of the TCA studies suggested that small studies 
with a small effect size might be missing (the funnel 
plot is not shown). The funnel plot methodology gives 
a qualitative view of publication bias but not a quantita-
tive perspective and is therefore diffi cult to interpret.
The relative risk for adverse effects leading to study 
withdrawal for TCAs was 2.35 (95% CI, 1.59 to 3.46) 
(Figure 4) and for SSRIs the relative risk was 2.01 (95% 
CI, 1.1 to 3.7) (Figure 5). The number needed to harm 
in terms of study withdrawal resulting from adverse 
effects for 2 statistically signifi cant TCA studies was 
5 and 10. None of the 4 SSRI studies had statistically 
signifi cant fi ndings for adverse effects leading to with-
drawal, but using the pooled fi gure and the range of 
baseline risks, the number needed to harm ranged from 
21 to 94. 
Seven studies did not meet the minimum quality 
criteria on at least 1 of the key components of method-
ological quality.18,22,25,27-29 A score of 0 on any compo-
nent caused the study to be rated as being poor quality. 
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Only 4 studies used an intention-to-treat analysis, and 
these studies were the most recent. When studies of 
low methodological quality for the TCAs (n = 6) were 
removed from analysis, the pooled standardized mean 
difference or depression score for TCA vs placebo was 
-0.50 (95% CI, -0.65 to -0.35). For improvement for the 
TCAs the relative risk was 1.34 (95% CI, 1.16 to 1.55). 
When studies in which at least one half of its asses-
sors were family practitioners were pooled, the stan-
dardized mean difference was -0.43 (95% CI, -0.58 to 
-0.28) and the relative risk was 1.2 (95% CI, 1.03 to 
1.4). There were suffi cient data to assess continuous out-
comes for TCAs at 1 week, 2 weeks, and 4 weeks. The 
standardized mean difference at 1 week was -0.02 (95% 
CI, -0.17 to 0.13), at 2 weeks it was -0.2 (95% CI, -0.36 
to -0.04), and at 4 weeks it was -0.34 (95% CI, -0.5 to 
-0.18). For studies that used a HAMD <8 as an outcome 
(considered to be a remission) the weighted mean dif-
ference was -3.68 (95% CI, -5.89 to -1.47). For the 3 
studies that reported no confl ict of interest, the weighted 
mean difference was -4.59 (95% CI, -6.82 to 2.36). 
Ten studies included an arm with 100 mg or more 
of a tricyclic antidepressant or more than 60 mg of 
mianserin. For the 10 studies in which a high dose 
was given, the standardized mean difference was -0.42 
(95% CI, -0.56 to -0.29). The relative risk for these 
studies was 1.32 (95% CI, 1.15 to 1.5). For the 4 stud-
ies of tricyclic antidepressants using a dose of 100 mg/d 
or less, the weighted mean difference (all used the 
HAMD) was -3.15 (95% CI, -5.05 to -1.24). For the 2 
studies of tricyclic antidepressants using a dose of 75 
mg/d, the weighted mean difference was -3.93 (95% 
CI, -7.65 to -0.21).
Most studies had heterogeneous diagnoses in their 
participants. Only 2 TCA studies had major depressive 
disorder as the single diagnosis, and the weighted mean 
difference for that study was -1.37 (95% CI, -2.52 to 
-0.22).19,29 For the SSRI studies there were 4 studies 
Table 1. Features of 15 Randomized Trials Comparing Either a Selective Serotonin Reuptake Inhibitor 
(SSRI) or Tricyclic Antidepressant (TCA) With Placebo
Study Quality* Diagnosis
TCA
Dose†
Responsible
for Treatment
Competing
Interest
Study
Period Outcome
TCA vs placebo
Blashki et al26 High Heterogeneous High and low GP and 
psychiatrist
No 4 wk HAMD
Brink et al27 Low Heterogeneous High GP Yes 6 wk HAMD
Doogan & 
Langdon19‡
High MDD High GP Yes 6 wk MADRS 50%M
Feighner et al24 High Heterogeneous High Psychiatrist No 4 wk HAMD 50%H
Hollyman et al23 High Heterogeneous High Psychiatrist No 6 wk HAMD 50%H
Lecrubier et al25 Low Heterogeneous High Psychiatrist Yes 12 wk HAMD 50%H
Malt et al17‡ High Heterogeneous High GP Yes 24 wk MADRS 50%M
Mynors-Wallis 
et al21
High Heterogeneous High GP No 12 wk MADRS 
Philipp et al20 Low ModDD Low GP Yes 8 wk HAMD
Thompson & 
Thompson28
Low Heterogeneous Low GP No 4 wk HAMD
Thomson et al22 Low Heterogeneous High GP Yes 12 wk HAMD
Barge-Schaapveld  
& Nicholson29
Low MDD High Unclear Yes 6 wk HAMD
SSRI vs placebo
Doogan & 
Langdon19*
High MDD 100 mg sertraline GP Yes 6 wk MADRS 50%M
Lepola et al18 Low MDD 10 mg escitalopram Unclear Yes 8 wk MADRS 50%M
Malt et al17† High Heterogeneous 100 mg sertraline GP Yes 24 wk MADRS
Montgomery 
et al30
High MDD 10 mg escitalopram
or 20 mg 
citalopram 
Unclear Yes 4 wk MADRS
Wade et al16 High MDD 10 mg escitalopram Unclear Yes 8 wk MADRS
HAMD = Hamilton depression scale; 50%H = discrete outcomes where improvement is a greater than 50% reduction in HAMD; MADRS= Montgomery-Asberg Depres-
sion Rating Scale; 50%M = discrete outcomes where improvement is a greater than 50% reduction in the MADRS; heterogeneous = patients thought by their general 
practitioner to be depressed, which may or may not include patients with major depression as opposed to the studies with only patients with major depression; MDD = 
major depressive disorder; ModDD = moderate depressive disorder.
* Quality high if adequate sample size, concealment, description of treatment, representative sample, specifi ed inclusion, details of withdrawals, valid outcomes.
† High dose defi ned as majority of TCA treated patients receiving at least equivalent of 100 mg/d amitriptyline (60 mg mianserin).
‡ Study has 3 arms (SSRI vs TCA vs placebo).
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in which all participants had major depressive disor-
der.16,18,19,30 Only 3 of the 4 studies had data suitable for 
pooling, and the relative risk was 1.39 (95% CI, 1.21 
to 1.61).
DISCUSSION 
We believe our systematic review is the fi rst to compare 
the effi cacy of antidepressants with placebo in the pri-
mary care setting. Our results confi rm that both TCAs 
and SSRIs are signifi cantly more effective than placebo 
for discrete and continuous outcomes. The results seem 
to apply to major depressive disorder and heterogeneous 
depression (commonly seen in primary care) and suggest 
that treating depression with antidepressants is an appro-
priate activity in primary care. We can only speculate as 
to the composition of the heterogeneous group, as they 
had a wide range of defi nitions but did consider patients 
with levels of depression less than major depression. 
Only 1 study analyzed major and minor depression and 
found no effect for minor depression.23
We found only 15 studies based in primary care that 
met inclusion criteria and provided evidence for the 
comparative effi cacy of TCAs and SSRIs vs placebo. 
We similarly found relatively few studies in a previous 
review of trials comparing SSRIs with TCAs in primary 
care,13 as opposed to the considerably larger number 
of studies conducted with patients from all settings. 
Williams et al31 found 206 studies comparing a newer 
with an older antidepressant (123 of which involved an 
SSRI). They found a benefi t for the newer antidepres-
sants (RR = 1.6, 95% CI, 1.3 to 2.3). Steffens et al, in 
a US-only based review, found 36 trials comparing a 
tricyclic with an SSRI.32 Most studies included in our 
Figure 2. Tricyclic vs placebo for improvement.
Figure 3. SSRI vs placebo for improvement.
0.01 0.1 1 10 100
Favors placebo Favors treatment
Study or 
Subcategory
Treatment 
n/N
Control 
n/N
RR (Fixed) 
95% CI
Weight 
%
RR (Fixed) 
95% CI
Feigher et al24 37/53 13/30 7.31 1.61 (1.03-2.52)
Thomson et al22 13/21 5/15 2.57 1.86 (0.84-4.09)
Hollyman et al23 53/67 39/74 16.32 1.50 (1.17-1.92)
Doogan & Langdon19 48/96 40/90 18.18 1.13 (0.83-1.53)
Mynors-Wallis et al21 10/31 1/30 0.45 9.68 (1.32-71.04)
Lecrubier et al25 24/37 28/45 11.13 1.04 (0.75-1.45)
Malt et al17 65/121 60/129 25.58 1.15 (0.90-1.48)
Phillipp et al20 73/109 30/47 18.46 1.05 (0.82-1.35)
Total (95% CI) 535 460 100.00 1.26 (1.12-1.42)
Total events: 323 Treatment, 216 Control
Test for heterogeneity: 2 = 12.36, 
df = 7 (P = .09), I2 = 43.4%
Test for overall effect: Z = 3.89 
(P <.0001)
0.1 0.2 0.5 1 2 5 10
Favors control Favors treatment
Study or 
Subcategory
Treatment 
n/N
Control 
n/N
RR (Fixed) 
95% CI
Weight 
%
RR (Fixed) 
95% CI
Wade et al16 90/191 64/189 28.16 1.39 (1.08, 1.79)
Doogan & Langdon19 50/83 40/90 16.80 1.36 (1.01-1.81)
Malt et al17 74/122 60/129 25.53 1.30 (1.03-1.65)
Lepola et al18 96/156 67/154 29.51 1.41 (1.14-1.76)
Total (95% CI) 552 562 100.00 1.37 (1.21-1.55)
Total events: 310 Treatment, 231 Control
Test for heterogeneity: 2 = 0.27, 
df = 3 (P = .97), I2 = 0%
Test for overall effect: Z = 5.03 
(P <.00001)
ANNALS OF FAMILY MEDICINE ✦ WWW.ANNFAMMED.ORG ✦ VOL. 3, NO. 5 ✦ SEPTEMBER/OCTOBER 2005
454
TCAS AND SSRIS VS PLACEBO FOR DEPRESSION
current review were small, phase 3 studies supported 
by commercial funding (Table 1). In fact, all the SSRI 
vs placebo studies had some commercial involvement. 
Many studies reviewed were of low methodological 
quality, and nearly all studies were of short duration, 
typically 6 to 8 weeks. Our fi ndings are in keeping with 
a review of 108 studies of newer antidepressants that 
found both TCAs and SSRIs to be effective in treating 
depression.33 Previous reviews have tended to show 
that SSRIs are generally more tolerable than TCAs, but 
evidence is confl icting. Meta-analyses using dropout 
rates as an index of tolerability have varied fi ndings. 
While one review34 found no difference in dropout rates 
between SSRIs (32.3%) and TCAs (33.2%), another35 
found a small but statistically signifi cant lower dropout 
rate for SSRIs (30.8%) relative to TCAs (33.4%). In our 
review focusing only on primary care samples, we found 
dropout rates for SSRIs of 5.4% and TCAs of 12%. 
The numbers needed to harm for the withdrawals from 
the statistically signifi cant TCA studies ranged from 5 
to 11. In another review of antidepressants in primary 
care, the relative risk of withdrawal of patients resulting 
from side effects from SSRIs compared with TCAs was 
0.6 (95% CI, 0.6 to 0.88).13 The National Institute of 
Clinical Evidence (UK NICE ) review group of antide-
pressants considered a weighted or a standardized mean 
difference of 3 or more to be clinically signifi cant (D 
Goldberg, personal communication, April 30, 2004). 
Figure 4. Tricyclic vs placebo for adverse effects leading to withdrawal.
Figure 5. SSRI vs placebo for adverse effects leading to withdrawal.
0.001 0.01 0.1 1 10 100 1000
Favors treatment Favors control
Study or 
Subcategory
Treatment 
n/N
Control 
n/N
RR (Fixed) 
95% CI
Weight 
%
RR (Fixed) 
95% CI
Brink et al27 3/27 1/25 3.16 2.78 (0.31-24.99)
Blashki et al 150 mg26 3/16 2/9 7.78 0.84 (0.17-4.16)
Blashki et al 75 mg26 4/13 3/9 10.78 0.92 (0.27-3.17)
Feighner et al24 12/93 3/50 11.86 2.15 (0.64-7.27)
Thomson et al22 7/31 0/28 1.59 13.59 (0.81-227.66)
Hollyman et al23 18/67 5/74 14.44 3.98 (1.56-10.12)
Doogan & Langdon19 2/108 3/101 9.42 0.62 (0.11-3.65)
Mynors-Wallis et al21 3/31 2/30 6.18 1.45 (0.26-8.09)
Lecrubier et al25 10/75 4/76 12.08 2.53 (0.83-7.72)
Malt et al17 18/121 7/129 20.69 2.74 (1.19-6.33)
Philipp et al20 1/110 0/47 2.12 1.30 (0.06-31.28)
Total (95% CI) 692 578 100.00 2.35 (1.69-3.46)
Total events: 81 Treatment, 30 Control
Test for heterogeneity: 2 = 9.29, 
df = 10 (P = .51), I2 = 0%
Test for overall effect: Z = 4.30 
(P <.001)
0.01 0.1 1 10 100
Favors treatment Favors control
Study or 
Subcategory
Treatment 
n/N
Control 
n/N
RR (Fixed) 
95% CI
Weight 
%
RR (Fixed) 
95% CI
Wade et al16 9/191 2/189 13.44 1.46 (0.97-20.34)
Doogan & Langdon19 6/108 3/101 20.73 1.66 (0.39-6.36)
Malt et al17 12/122 6/129 39.00 2.11 (0.82-5.46)
Lepola et al18 4/155 4/154 26.83 0.99 (0.25-3.90)
Total (95% CI) 576 573 100.00 2.01 (1.10-3.69)
Total events: 30 Treatment, 15 Control
Test for heterogeneity: 2 = 2.21, 
df = 3 (P = .53), I2 = 0%
Test for overall effect: Z = 2.26 
(P <.02)
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We have reported signifi cant numbers needed to treat, 
which are another way of assessing clinical signifi cance. 
Primary care clinicians may be more likely than hospital 
colleagues to alter therapy when side-effects are experi-
enced, even during clinical trials.36
Most systematic reviews concerning effi cacy of anti-
depressant medications fail to report a detailed exami-
nation of methodological quality and therefore fail to 
include such criteria when examining treatment effects. 
Bias in primary studies that is due to poor method-
ological quality (eg, selection bias, ascertainment bias, 
inappropriate handling of withdrawals, protocol viola-
tions) can lead to exaggeration of treatment effects. A 
study of trial quality in systematic reviews showed that 
if low-quality studies were included in pooled estimates 
of treatment effect, there was a 30% to 50% exaggera-
tion of treatment effectiveness.37 We did not, however, 
fi nd any appreciable differences between effects for the 
high-quality studies compared with the lower quality 
studies. Another form of bias with meta-analysis is that 
of publication bias. Our funnel plot suggests that small 
studies with small effect sizes may be missing. This 
fi nding is consistent with a review of all applications 
to the US Food and Drug Administration, which, on 
examination of all submitted trials of newer antidepres-
sant medications, found that the benefi t of antidepres-
sant medications was much smaller when all studies 
were considered than when only the published studies 
were considered.38 The use of standardized mean dif-
ference was necessary, as the studies with continuous 
outcomes used a number of different scales—HAMD in 
the older studies and MADRS in more recent years. It 
would be helpful for future meta-analyses for both the 
HAMD and MADRS to be used to facilitate pooling.
Our fi nding of a signifi cant benefi t when pooling 
the results of 2 studies is consistent with a recent meta-
analysis of studies in all settings, which found a benefi t 
from treatment with low-dose tricyclic antidepres-
sants.39 Neither of the fi ndings from the 2 studies in 
our review were statistically signifi cant, which suggests 
that larger trials are needed in the primary care setting 
to clarify such issues as dose of antidepressant medica-
tion.26,28 The review of studies of low-dose medications 
found that no evidence of increased benefi t, but there 
was an increase in side effects with higher dosages. Our 
results were similar to those of that review, but we did 
not fi nd a signifi cant increase in adverse effects. 
Most of the trials reviewed here studied patients 
with a range of depression severity. Only 2 TCA stud-
ies included patients with major depressive disorder.19,29 
Three studies of SSRIs included only patients with major 
depressive disorder.16,18,19 As patients in primary care 
settings have a range of depression severity, the gener-
alizability of the results of these studies to primary care 
is reasonable.40 Advice on using TCAs has stressed that 
patients will not obtain a benefi t from medication until 2 
weeks of treatment has passed. Our fi ndings are in agree-
ment. Also at issue is that primary care populations may 
benefi t from antidepressant medication only when it is 
given by a psychiatrist. Our signifi cant fi ndings for con-
tinuous and discrete outcomes contradict this concern. 
We found evidence that both TCAs and SSRIs are 
more effective than placebo. This fi nding needs to be 
tempered with the knowledge that some publication 
bias may have occurred and that many studies in the 
review were small and of variable quality. Gaps in the 
literature include a lack of attention to the treatment 
of specifi c diagnostic groups, in particular patients with 
minor depression. Further research is needed on these 
groups of patients in addition to longer and larger 
trials of low-dose TCAs. In terms of practice, many 
guidelines are recommending SSRIs rather than TCAs 
because of safety. Both are effective, and if safety is not 
an issue, then individual tolerability to side effects will 
determine types of medications used.
To read or post commentaries in response to this article, see it 
online at http://www.annfammed.org/cgi/content/full/3/5/449.
Key words: Antidepressant agents, tricyclic; antidepressive agents, sec-
ond-generation; placebo; primary health care
An earlier form of this review was presented at the Annual Scientifi c 
Meeting of the North Atlantic Primary Care Research Group, October 
2003. It was awarded an extended paper award.
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